Home - Quirem Medical

You are unique, and your treatment should be too.

To learn more about Selective Internal Radiation Therapy (SIRT) for treating liver cancer and the unique benefits of our products, visit our patient information website.

LifeHAck

Introducing Q-Suite™

Q-Suite™ is software for dosimetric verification of Ho-166 SIRT. A workflow-based user interface makes Q-Suite™ easy to learn and use.

LEARN MORE

Events

Meet us in Nice at ECIO 2020

The Quirem team will attend ECIO in Nice from April 26-29 2020.

Visit the ECIO website

SIRT in three steps

Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to improve patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in three simple steps:

1. SELECT

Select only those patients that are likely to benefit from SIRT. Use QuiremScout^®, a safe dose of holmium microspheres, to evaluate the biodistribution of particles prior to therapy in your patients.

2. TREAT

Treat with QuiremSpheres^®, the next-generation microspheres, indicated for treatment of unresectable liver tumors. Click here to learn what value QuiremSpheres® can bring to your clinic.

3. VERIFY

Use our software package Q-Suite^TM to determine SIRT succes right after the procedure, by evaluating the absorbed dose in the lesions and normal liver tissue

News and events

Dose-response relation confirmed for Holmium-166 (QuiremSpheres®) SIRT

Quirem Medical is pleased to share that yet another Holmium-166 (QuiremSpheres®) related scientific article has been published, after recently having reported on the publication of Smits et al. on the superior predictive value of 166Ho-Scout

November 15, 2019

Radboud university medical center and Quirem Medical sign cooperation agreement

Radboud university medical center and Quirem Medical today signed an agreement for joint research. The agreement includes several existing and future projects based on small radioactive spheres (holmium-166 microspheres). Enhanced cooperation should improve the treatment

October 22, 2019

QuiremScout® superior in predicting intrahepatic dose distribution

In their study, Smits et al. showed that QuiremScout® is a superior predictor of intrahepatic dose distribution compared to Tech-99m-MAA. The results of their study were published online on the 9th of August 2019 in

August 23, 2019

What our customers say

“QuiremSpheres^® gives us the confidence we need to start individualizing treatments.”

"QuiremScout^® enables us to evaluate the safety and efficacy profile of SIRT, prior to the therapeutic procedure. We can now select and treat only those patients that are likely to benefit from SIRT."

“The short halftime of holmium-166 in QuiremSpheres^® results in a high initial dose rate. Therefore, we expect to see an improved radiobiological effect.”

Zutphenseweg 55

7418AH Deventer

The Netherlands

Telephone: +31 85 0404170

E-mail: info@quirem.com